Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

OriGene to Acquire SDIX's Life Science Business Assets



            OriGene to Acquire SDIX's Life Science Business Assets

PR Newswire

ROCKVILLE, Md., April 8, 2013

ROCKVILLE, Md., April 8, 2013 /PRNewswire/ -- OriGene Technologies, Inc., a
leading genome wide product company for research and diagnostic applications
with operations in the United States and China, announced that it has signed a
definitive agreement to acquire all the assets of the Life Science business of
SDIX™ (NASDAQ: SDIX), a leading provider of biotechnology-based products and
services. 

(Logo: http://photos.prnewswire.com/prnh/20130408/DC90285LOGO)

"We anticipate the combination of SDIX with OriGene will enhance our ability
to continue to develop the most comprehensive collection of high-quality
monoclonal antibodies for key applications both in research and diagnostics
fields.  SDIX's over 20 years of antibody development and production expertise
will complement OriGene's existing high-throughput monoclonal antibody
capacity to develop the highest quality antibodies such as UltraMAB™," said
Wei-Wu He, Ph.D., OriGene's Chairman and Chief Executive Officer.  OriGene
expects the acquisition of SDIX to:

  o Enhance the capabilities of OriGene to provide the most comprehensive
    immunization strategies for antibody development using full-length
    mammalian produced protein and genetic immunization technologies to create
    the highest quality monoclonal antibodies available
  o Expand antibody and IVD reagent product and services capabilities to
    create significant new commercial opportunities for our existing and new
    customers including producing UltraMAB™ for future diagnostic uses

This transaction will uniquely position OriGene as one of the leaders in
antibody development and production to help our customers find the best
solutions for their antibody and assay needs.  The acquisition is expected to
be completed during the second quarter of 2013, subject to the approval of
SDIX's shareholders and other customary closing conditions.

About OriGene Technologies

OriGene Technologies, Inc. develops, manufactures, and sells genome wide
research and diagnostic products worldwide.  OriGene has developed an
extensive array of ultra-specific monoclonal antibodies called UltraMAB™ which
offers significant improvement over traditional antibodies in antibody
specificity.  UltraMAB™ antibodies are validated by OriGene's proprietary high
density microarray technology for a wide variety of antibody applications. 

For more information, visit www.origene.com.

SOURCE OriGene Technologies, Inc.

Website: http://www.origene.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement